Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on March 23, 2017. The filing serves to report a material change and incorporates a Material Change Report (Exhibit 99.1) dated March 23, 2017. The document is incorporated by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
The filing explicitly references a "Material Change Report" dated March 23, 2017, as Exhibit 99.1. However, the specific details of the material change are not described in the cover text of this Form 6-K.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or details regarding unusual items. These details are expected to be contained within the referenced Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Material Change Report) to understand the specific nature of the reported material change.
- Verify the status of the Registration Statement on Form F-10 (File No. 333-206994) into which this report is incorporated.
- Consult the company's most recent Form 40-F or quarterly reports for actual financial metrics, as none are present in this filing.